Thrombotargets Corporation
2530 Meridian Parkway
Suite 3024
Durham
North Carolina
27713
United States
Tel: 919-806-4254 / 919-806-4322
Fax: 919-806-4870
Website: http://www.thrombotargets.com/
About Thrombotargets Corporation
Thrombotargets is an innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and small molecule drug technologies. Thrombotargets´s programs leverage the company’s haemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.Thrombotargets group is comprised by three companies; Thrombotargets Corporation (Durham, NC, USA.) is responsible for Drug Development and Business Managment; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead Validation, Lead Optimization and High Througput Screening and Biotech Libraries (Girona, Spain) for engineered targeted libraries.
Thrombotargets´s strategy is to build stockholder value by discovering new leads and advancing them to clinical phases.
With a primary focus on therapeutics for Haemostasis and Thrombotic diseases, Thrombotargets´s objective is to identify, optimize and develop highly efficacious biotech and small molecule leads with low risk profiles and large market opportunities.
Thrombotargets will achieve their objectives by operating a balanced risk business strategy:
1. Invest in our own discovery and development programs and drive these through to clinical phases before partnering the candidate with pharmaceutical companies. Thrombotargets will be compensated for this innovation and effort primarily through license fees, milestones and royalties on drug sales. 2. Collaborate with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies. 3. Through the in-licensing of programs at stages of development that complement and balance our existing internal portfolio, Thombotargets leverage external innovation
Proprietary Technology Thrombotargets has developed and adapted to High Throughput Screening (HTS), a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary HTS Platforms named BioPlatformScreenTM, the Thrombotargets group is creating a continuously novel and promising pipeline. Presently, two of Thrombotargets most innovative drug candidates, TH-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel anticoagulant monoclonal antibody, are undergoing Preclinical trials; these programs will begin Phase I clinical trials Q4, 2007. Recently we begun a new antifibrinolytic program (TT-111 and TT-112) in collaboration with ASINEX, Rusia due to results in the explotation of our BioplatformScreen Technology.
Current Alliances
Intellectual Property Status Thrombotargets patents state protect our intellectual property and permit the commercialization of our technologies and compounds.
Board of Directors
Last Updated: 07-20-2007
6 articles about Thrombotargets Corporation
-
Thrombotargets Corporation and Dr. Cam Patterson to Create a Joint Venture
7/3/2007
-
Thrombotargets Corporation and Magellan Bioscience Group, Inc. to Collaborate
6/14/2007
-
Steven Hite Appointed Chief Operating Officer of Thrombotargets Corporation
6/14/2007
-
Thrombotargets Corporation Announces the Membership of its Scientific Advisory Board
6/1/2007
-
Thrombotargets Corporation Relocates to Research Triangle Park in North Carolina
4/23/2007
-
Thrombotargets Corporation Europe Inagurates New Facilities at the National Biotechnology Center in Madrid, Spain
2/1/2007